Banks, venture capital companies and other financial institutions are constantly evaluating opportunities to invest in technology-based companies. Given the number of technology firms seeking funding, the issue for investors is whether you have the time as well as the experience and technical expertise to review these companies critically and assess their ability to deliver. The key question that needs to be answered is: 'Does this opportunity present a secure investment?'
Technology as the differentiating factor
In an increasingly complex and competitive environment, technology providers have become key players in the industry. There are many such providers, ranging from general biotechnology firms that focus on the creation of biological products to proteomic and pharmacogenomic companies offering specific enabling technologies and services. We believe that, in this context, the technology can be a differentiating factor between companies that simply have attractive business strategies and those that can actually deliver on those strategies.
Assessing business strategies as well as the technology
Through our services in technology evaluation, PA can help you determine whether the companies you are considering constitute sound investments. Through an appraisal of the company's technology platform, PA can answer questions such as: How reliable is the technology and the science behind it?
However, technology alone will not make a company successful. A business also needs a clear vision that is supported by a solid business strategy and by a capable management team. Our assessment, therefore, is not simply technology-based. We also review commercial and operational issues: the markets, competitors, the firm's business strategy, its development plans and its ability to deliver.
Why is PA uniquely positioned to deliver this kind of solution?
We combine the rich technical and commercial expertise of multi-disciplinary teams with an in-depth analysis of technologies, markets, trends and industry models to develop our comprehensive view of your investment opportunity. PA has successfully applied this method over the years, enabling us to becoming a leading provider of technology evaluations and due diligence to the finance community.
Since 1997 PA has provided due diligence in life science technology business transactions exceeding $1.5 billion
Further information
For further information please e-mail: healthcare@paconsulting.com
